Peripheral artery disease (PAD) affects >235 million people globally, and the prevalence is increasing. Intermittent claudication (IC) is a common symptom in patients with PAD characterized by muscle discomfort in the lower limb that is provoked by exercise and relieved by rest and is associated with reduced ambulatory activity and quality of life. Participation in supervised exercise therapy (SET) programs increases the walking capacity of patients with IC and is the first-line treatment, together with smoking cessation and pharmacologic secondary prevention. However, the availability of SET programs is low, and many patients are unwilling or unable to participate. Consequently, home-based exercise programs and different treatment devices have been suggested as alternative treatment options.

Methods using intermittent negative pressure (INP) applied to the lower body or extremities to improve...
blood flow in patients with PAD have been described since the early 20th century.\textsuperscript{13-15} Several studies have suggested positive effects on walking distance in patients with IC.\textsuperscript{16-18} However, two recent studies did not find any additional effects of INP treatment on walking capacity.\textsuperscript{19,20} Because the treatment intensity and duration varies among previous studies and the results differ, the clinical effect of INP treatment for patients with IC remains uncertain.

The aim of the present study was to investigate the clinical effects of treatment with \(-40\) mm Hg INP for 1 hour in the morning and 1 hour in the evening for 12 weeks in patients with IC. We hypothesized that this treatment would improve the pain-free walking distance (PWD) and maximal walking distance (MWD) compared with sham treatment.

**METHODS**

**Participants.** We performed a multicenter trial, enrolling patients from the outpatient clinics at three vascular surgery departments in Norway (Oslo University Hospital, Oslo; Sørlandet Hospital, Kristiansand; and St Olav Hospital, Trondheim) from January to September 2019. Data collection was completed in December 2019. Patients with an ankle-brachial index (ABI) of \(\leq 0.9\) or incompressible arteries and a radiologic diagnosis of PAD and IC were assessed for eligibility. Patients who had been scheduled for or who had undergone endovascular or open surgical revascularization within the previous 3 months were considered ineligible. The exclusion criteria were: inability to provide an informed consent; inability to perform a treadmill test; inability to independently operate the treatment device; the presence of severe heart disease; the presence of severe chronic obstructive pulmonary disease; and a baseline MWD of \(>1000\) m measured on a treadmill with a ramp protocol.\textsuperscript{21} All patients were offered the best medical treatment according to the guidelines from the European Society of Cardiology and the European Society for Vascular Surgery.\textsuperscript{7}

**INP treatment.** INP was applied in a pressure chamber sealed around the lower leg. A pump unit (FlowOx 2.0; Otivio AS, Oslo, Norway) removed air from, and vented, the pressure chamber (Fig 1), producing alternating 10 seconds negative pressure and 7 seconds atmospheric pressure. The patients in the treatment group received \(-40\) mm Hg INP, and the sham control group received \(-10\) mm Hg INP. The devices were otherwise identical. These INP levels were chosen according to the findings from a recent study from our research group demonstrating that \(-40\) mm Hg INP induced an acute increase in blood flow in the treated extremity in patients with PAD, in contrast to \(-10\) mm Hg INP which did not significantly affect blood flow.\textsuperscript{22}

All patients were instructed to treat themselves at home for 1 hour in the morning and 1 hour in the evening for 12 weeks. They were trained in the use of the INP device before the start of treatment. The daily treatment time was recorded by the device, allowing for the analysis of compliance data after the intervention period. To avoid the direct effects of treatment on the test results, the patients were instructed not to use the device on the day of the 12-week follow-up examination.

**Randomization and blinding.** Patients were randomized to the treatment group or sham control group in a 1:1 ratio using a computer-generated randomization list. Labeling of the treatment devices was performed by the producer (Otivio AS) by a person not involved in patient recruitment or data collection. The patients and personnel with patient contact during the study period were unaware of the group allocation. The statistical analyses were also performed without knowledge of the treatment group.

**Clinical evaluation and measurements.** Clinical evaluation and measurements were performed by the same person at baseline and after 12 weeks of treatment. The primary outcome measures were the changes in PWD and MWD. The pain-free walking time and maximal walking time were measured with the patients walking on a treadmill using a ramp protocol at a constant speed of 3.2 km/h starting at a 0\% slope and increasing the slope by 2\% every 2 minutes.\textsuperscript{21} The patients were asked to specify the most limiting leg after the baseline treadmill test, which was chosen as the treatment leg. Before the treadmill test, the resting ABI was measured with the patient in a supine position according to the guidelines from the American Heart Association.\textsuperscript{23}
Postischemic blood flow was measured with the patient in supine position within 1 minute after the end of the treadmill test. Resting blood flow was measured with the patient in the supine position using strain-gauge plethysmography (Domed Filtrass Angio, Krailling, Germany) of the lower leg at the point of maximal circumference. The plethysmograph records the rate of change in volume expansion for the area under the strain-gauge during proximal venous occlusion on the thigh, and the blood flow values are calculated. Postischemic blood flow was measured using the same strain-gauge plethysmograph after 3 minutes of arterial occlusion obtained by inflating the thigh cuff to 250 mm Hg. For safety reasons, patients who had previously undergone bypass surgery in the leg were excluded from the present examination, as were patients who experienced unbearable pain during occlusion.

All the patients were requested to complete the EQ-5D-5L and Vascuql-6 quality of life questionnaires at baseline and after 12 weeks of treatment. The EQ-5D-5L questionnaire consists of a visual analog scale and a descriptive system. Using each patient’s score in the descriptive system, an index value was calculated (EQ-5D-5L index) based on a value set validated for Denmark. The Vascuql-6 is a health-related quality of life questionnaire for patients with PAD validated for Norway, consisting of six disease-specific items with a total score ranging from 6 to 24, with a higher score indicating better health.

**Statistical analysis.** The data are presented as the mean ± standard deviation for continuous variables and numbers and percentages for categorical variables, unless otherwise stated. Normality was assessed by histograms, Q-Q plots, and residual plots. The baseline characteristics between the groups were compared using independent samples t-tests for continuous variables and χ² tests for categorical variables. Differences within the groups were analyzed using paired sampled t-tests. Differences between groups were evaluated using univariate analysis of covariance, adjusting for differences in baseline data. All subjects with pre- and post-treatment data were included in the intention-to-treat analyses. P values ≤.05 were considered statistically significant. Analyses were performed using Stata, version 16 (StataCorp, College Station, Tex).

In a comparable population of patients with IC, the pain-free walking time on a treadmill was 146 ± 112 seconds. Assuming an increase in pain-free walking time of 87 seconds (76 m) as a clinically important difference, 26 patients per treatment arm were required to detect a treatment effect, given 80% power and a 5% significance level. Assuming a withdrawal rate of 25%, we aimed to include 35 patients in each group.

**Ethics.** The Regional Committee for Medical and Health Research Ethics in Norway approved the present study (reference no. 2018/748), which was registered at ClinicalTrials.gov (identifier, NCT03640676). All the patients provided written informed consent before inclusion.

**RESULTS**

A total of 85 patients were assessed for eligibility. Of the 85 patients, 2 did not meet the inclusion criteria (baseline MWD >1000 m), and 11 patients declined to participate, leaving 72 patients (85%) for randomization (Oslo University Hospital, n = 46; St Olavs Hospital, n = 5; Sørlandet Hospital, n = 21; Fig 2). At baseline, a significantly higher prevalence of diabetes was present in the treatment group compared with the sham control group (P = .008). No significant differences were found between the two groups for all other demographic variables (Table I).

**Walking distance.** The between-group comparisons showed a significant difference in the change in the PWD, favoring the treatment group compared with the sham control group (estimated treatment effect, 50 m; 95% confidence interval [CI], 11-89; P = .014; Table II). At baseline, the PWD was 109 ± 70 m in the treatment group and 111 ± 77 m in the sham control group (Table I). After 12 weeks of treatment, an increase in the PWD of 68 m had occurred in the treatment group (95% CI, 33-103; P < .001) and 18 m in the sham control group (95% CI, −1 to 38; P = .064; Fig 3).

The between-group comparisons showed no significant differences in the change in the MWD after 12 weeks of INP treatment (estimated treatment effect, 42 m; 95% CI, −14 to 97; P = .14; Table II). The baseline MWD was 267 ± 177 m in the treatment group and 263 ± 170 m in the sham control group (Table I). After 12 weeks of

---

**Table I**

| Group               | PWD Baseline (m) | PWD Change (m) |
|---------------------|------------------|-----------------|
| Treatment           | 109 ± 70         | 68              |
| Sham control        | 111 ± 77         | 18              |

**Table II**

| Group               | MWD Baseline (m) | MWD Change (m) |
|---------------------|------------------|-----------------|
| Treatment           | 267 ± 177        | 0               |
| Sham control        | 263 ± 170        | 0               |
treatment, an increase had occurred in the MWD of 62 m in the treatment group (95% CI, 19-105; \( P = \) .006) and 20 m in the sham control group (95% CI, 16 to 57; \( P = \) .27; Fig 3).

Of the 63 patients who had completed the 12-week intervention period, 56 (89%) had had a baseline PWD of <200 m. For these patients, the between-group comparisons showed statistically significant differences in the changes in both PWD and MWD, favoring the treatment group (estimated treatment effect, 42 m; 95% CI, 2-83; \( P = \) .042; and estimated treatment effect, 62 m; 95% CI, 5-118; \( P = \) .032, respectively; Table III).

**ABI, blood flow measurements, and quality of life.** At baseline, the resting ABI was 0.53 ± 0.16 in the treatment group and 0.56 ± 0.15 in the sham control group (Table I). No significant changes were found in the resting or postexercise ABIs across the groups (\( P = \) .65 and \( P = \) .19, respectively), and the plethysmography measurements did not show significant changes in the resting or postischemic blood flow across the groups (\( P = \) .34 and \( P = \) .58, respectively) after 12 weeks of treatment. Furthermore, no significant changes were observed in the quality of life questionnaire scores (EQ-5D-5L index, \( P = \) .67; EQ-5D-5L visual analog scale score, \( P = \) .29; Vascuqol-6, \( P = \) .89) across the groups after 12 weeks of treatment (Table II). Relative within-group changes for all outcome variables after 12 weeks of treatment are illustrated in the Supplementary Fig (online only).

**Compliance, discontinuation, and adverse events.** The mean daily treatment time was 1.8 ± 0.2 hours in the treatment group and 1.8 ± 0.5 hours in the sham control group (\( P = \) .63). Six patients in the treatment group and three patients in the sham control group were lost to follow-up (Fig 2). Four patients in the treatment group discontinued treatment because of issues related to use of the treatment device. One patient in the treatment group and one patient in the sham control group discontinued treatment because of severe trauma (ankle fracture and hip fracture, respectively), and one patient in the sham control group discontinued because of surgery for pulmonary cancer. One patient in each group died, both of cardiac arrest (unrelated to the INP sessions) during the 12-week intervention period. No further serious adverse events were reported.

**DISCUSSION**

The main finding from the present study was that treatment with –40 mm Hg INP for 1 hour in the morning and 1 hour in the evening for 12 weeks increased the PWD compared with sham treatment for patients with IC. For the patients with a baseline PWD of <200 m
clinically classified as Fontaine IIb, corresponding to Rutherford class 2-3), both PWD and MWD increased in the treatment group compared with the sham control group.

To the best of our knowledge, the present study is one of the first double-blind randomized controlled trials to show that INP treatment increases the walking distance for patients with IC. Our findings are in line with the results reported by a placebo controlled study from Denmark, which also described an effect on walking distances. However, only the within-group changes had been reported in that study. Older studies have reported similar findings for patients with PAD, but these were mainly case reports and patient series. However, two recent placebo controlled trials concluded that INP treatment does not provide additional effects to SET or home-based physical activity and lifestyle changes in increasing the walking capacity in patients with IC. One explanation might be that the effect of increased physical activity surpasses the potential effects of INP treatment. Another explanation might be that the patients were treated with INP for only 30 and 40 minutes two and three times each week for 6 weeks, respectively, because that INP system required in-hospital treatment instead of at-home treatment. Hence, the frequency and length of the INP treatments were significantly lower than those used in the present study.

### Table I. Baseline patient characteristics

| Variable                      | Treatment group (n = 38) | Sham control group (n = 34) | P value |
|-------------------------------|--------------------------|-----------------------------|---------|
| Age, years                    | 72 ± 8                   | 73 ± 6                      | .59a    |
| Male sex                      | 25 (66)                  | 26 (76)                     | .32b    |
| Body mass index, kg/m²        | 27.3 ± 4.2               | 26.9 ± 4.0                  | .74a    |
| Smoking                       |                          |                             |         |
| Current                       | 14 (37)                  | 11 (32)                     |         |
| Previous                      | 19 (50)                  | 18 (53)                     |         |
| Never                         | 15 (39)                  | 5 (15)                      |         |
| Comorbidity                   |                          |                             |         |
| Diabetes mellitus             | 18 (47)                  | 6 (18)                      | .008b   |
| Chronic renal failure         | 5 (13)                   | 4 (12)                      | .86b    |
| Hypertension                  | 32 (84)                  | 28 (82)                     | .83b    |
| Hypercholesterolemia          | 22 (58)                  | 27 (79)                     | .051b   |
| Coronary artery disease       | 17 (45)                  | 18 (53)                     | .49b    |
| Cerebrovascular disease       | 8 (21)                   | 8 (24)                      | .80b    |
| Antiplatelet agent            | 32 (84)                  | 27 (79)                     | .60b    |
| Anticoagulant agent           | 6 (16)                   | 8 (24)                      | .41b    |
| Statin                        | 32 (84)                  | 31 (91)                     | .37b    |
| Antihypertensive agent        | 34 (89)                  | 31 (91)                     | .81b    |
| Treated leg, right            | 19 (50)                  | 22 (65)                     | .21b    |
| Disease location              |                          |                             | .81b    |
| Suprainguinal                 | 6 (16)                   | 4 (12)                      |         |
| Infrainguinal                 | 23 (61)                  | 23 (68)                     |         |
| Supra- and infrainguinal      | 9 (24)                   | 7 (21)                      |         |
| Previous revascularization in treated leg | 16 (42) | 12 (35) | .55b |
| PWD, m                        | 109 ± 70                 | 111 ± 77                    | .90b    |
| MWD, m                        | 267 ± 177                | 263 ± 170                   | .94b    |
| Resting ABI                   | 0.53 ± 0.16              | 0.56 ± 0.15                 | .33b    |
| Postexercise ABI              | 0.35 ± 0.17              | 0.33 ± 0.13                 | .52b    |
| Vascuqol-6                    | 13.4 ± 3.0               | 13.7 ± 3.3                  | .68b    |
| EQ-5D-5L index                | 0.65 ± 0.20              | 0.70 ± 0.12                 | .20b    |

ABI, Ankle-brachial index. MWD, maximal walking distance. PWD, pain-free walking distance.

Data presented as mean ± standard deviation for continuous variables and as number (%) for categorical variables.

aIndependent samples t-test.
bχ² Test.
rhythmical fluctuations in blood flow, which might promote long-term favorable effects leading to an increased walking capacity. It is reasonable to assume that a higher treatment frequency would be favorable and might also be necessary to achieve clinical effects.

In patients with a baseline PWD of <200 m, we observed an increase in both PWD and MWD in the treatment group compared with the sham control group. Although determined from a subgroup analysis, this finding indicates that the patients with the most symptomatic disease might benefit the most from INP treatment. Multiple studies have documented the beneficial effects of SET programs on walking capacity, functional status, and quality of life in patients with IC. However, a systematic review from 2016 concluded that only one third of patients with IC were suitable for or willing to undertake SET. Hence, the current guidelines recommending SET might not be applicable to most patients with IC. Although SET should be the first choice of treatment for patients with IC, INP treatment might be a useful supplement when SET is unavailable or for patients unable or unwilling to participate in SET.

The between-group changes in PWD in the present study were lower than assumed in the power calculations. Howev-er, to the best of our knowledge, no consensus has been reached regarding the minimal clinically important difference in walking performance after interventions in patients with IC. It is probably dependent on the disease severity, comorbidities, and the patient’s subjective judgment. Pharmacologic agents such as cilostazol and pentoxifylline have market approval in Europe and the United States, with an indication of improving leg symptoms in patients with IC. A Cochrane review from 2014 estimated that cilostazol could increase the PWD by 31 m (95% CI, 22-40) and MWD by 43 m (95% CI, 18-68) compared with placebo. Another Cochrane review from 2015 reported an improvement in PWD of 33.8% to 73.9% and in MWD of 1.2% to 156% with pentoxifylline. However, statistical tests were not performed because of insufficient data. In the present study, we found an estimated treatment effect on the PWD of 50 m and a treatment effect for patients with a PWD <200 m of 42 m for PWD and 62 m for MWD. Thus, INP treatment is competitive to drug treatment in increasing the walking capacity of patients with IC. Treatment of the calf or foot using intermittent pneumatic compression (IPC) has also been suggested to improve the walking distance for patients with IC. Both INP and IPC increase arterial blood flow acutely when applied to the lower limb, which might increase arterial shear stress, thereby inducing flow-mediated vasodilatation. However, IPC is applied over a smaller area on the calf or foot and might not have the same microvascular effects on the whole lower leg compared with INP.

Endovascular or open surgery can be considered for patients with IC who have severely disabling symptoms and do not respond to SET. A Cochrane review from

| Variable | No. available for analysis | Estimated treatment effect (95% CI) | P value |
|----------|---------------------------|------------------------------------|---------|
| PWD, m   | 63                        | 50 (11-89)                         | .014    |
| MWD, m   | 63                        | 42 (−14 to 97)                     | .14     |
| Resting ABI | 60                        | 0.01 (−0.04 to 0.07)               | .65     |
| Postexercise ABI | 47                        | 0.04 (−0.02 to 0.10)               | .19     |
| Blood flow, mL/100 mL tissue |                |                                    |         |
| Resting | 59                        | 0.5 (−0.6 to 1.6)                  | .34     |
| Postischemic | 53                        | 0.4 (−1.1 to 2.0)                  | .58     |
| Vascuqol-6 | 63                        | −0.11 (−1.53 to 1.31)              | .89     |
| EQ-5D-5L index | 57                        | 0.01 (−0.05 to 0.08)               | .67     |
| EQ-5D-5L VAS | 63                        | 5.3 (−4.7 to 15.4)                 | .29     |

ABI, Ankle-brachial index; CI, confidence interval; MWD, maximal walking distance; PWD, pain-free walking distance; VAS, visual analog scale.

Fig 3. Pain-free walking distance (PWD) (A) and maximal walking distance (MWD) (B) at baseline and after 12 weeks of treatment. Dots indicate mean values; error bars, standard errors.
2018, which compared endovascular revascularization and conservative treatment of IC, reported a moderate effect on MWD and a large effect on PWD after 6 to 12 months.\textsuperscript{45} However, no clear differences were shown between the groups after long-term follow-up.\textsuperscript{45} Different outcome measures and study designs did not allow for direct comparisons to the findings in the present study. However, the effect of INP treatment after 3 months should be subject to further research.

In the present study, we did not observe any differences across the groups in the resting or postexercise ABI after 12 weeks of treatment. This is in line with the findings from a systematic review on the effects of exercise on IC, reporting an increased walking capacity without finding significant changes in the ABI.\textsuperscript{3} Although we found an effect of INP treatment on walking distance, we did not find any differences in the quality of life parameters across the groups after 12 weeks of treatment. This does not correspond with the findings from studies investigating the effects of SET in IC.\textsuperscript{36,38} One explanation might be that the improvement in the quality of life after participation in SET is also related to other factors than just the improvement in walking distance, such as increased physical activity and social interactions, which might not be obtained using INP treatment alone. Another explanation might be that the present study was underpowered to detect changes in quality of life across the groups.

The treatment group received \textsuperscript{−}40 mm Hg INP, which is the standard INP level provided by the Conformitè Européenne–marked FlowOx system commercially available in Europe. This INP level seemed to be well tolerated, and it is possible that a higher level could have been used. However, in a previous study from our research group, we did not observe any significant difference in the acute increase in arterial or skin blood flow at \textsuperscript{−}60 mm Hg INP compared with \textsuperscript{−}40 mm Hg INP.\textsuperscript{22} Whether subgroups of patients could benefit from a higher INP level requires further investigation.

The prevalence of diabetes was higher in the treatment group than in the sham control group. Patients with diabetes are more prone to microangiopathy. Hence, the clinical effects observed in the present study could have resulted from positive effects on the arterial circulation or microcirculation, or both.

One patient in each group died of cardiac arrest during the intervention period. No clinical evidence was found to support a causal relationship between these events and the use of the treatment device or participation in the present study. The number of deaths in the present study did not allow for further statistical interpretations but underscores the high mortality for patients with symptomatic PAD.\textsuperscript{46}

The present study had some limitations. We used \textsuperscript{−}10 mm Hg INP in the sham device to make it appear identical to the active device without affecting the arterial blood flow. The similarity in compliance between the groups and the low withdrawal rate in the sham control group indicates that the patients really were unaware of their treatment allocation. However, a small effect might have resulted from the repetitive exposure to \textsuperscript{−}10 mm Hg INP, leading to an underestimation of the treatment effect. More patients were lost to follow-up in the treatment group than in the sham control group because of user- or device-related problems. The use of the device requires some technical, cognitive, and motor capacity. In addition, some patients with a very small circumference of the lower leg might experience difficulty in achieving airtightness of the pressure chamber. Hence, the difference in those lost to follow-up between the two groups might have been random. Measurements of PWD is based on a subjective report of the onset of pain by the patient during the treadmill test. Thus, the results might have been affected by the fact that individuals might perform differently when they are being observed. However, in a double-blind, randomized controlled trial, the risk of bias from this phenomenon seems low. The patients were recruited from

| Variable | No. available for analysis | Estimated treatment effect (95% CI) | P value |
|----------|---------------------------|-----------------------------------|---------|
| PWD, m   | 56                        | 42 (2-83)                         | .042    |
| MWD, m   | 56                        | 62 (5-118)                        | .032    |
| Resting ABI |                       | 0.00 (−0.06 to 0.06)              | .91     |
| Postexercise ABI |                 | 0.04 (−0.03 to 0.10)             | .27     |
| Blood flow, mL/100 mL tissue | | | |
| Resting | 53                        | 0.7 (−0.4 to 1.8)                 | .20     |
| Postischemic |                     | 0.3 (−1.4 to 2.0)                 | .74     |
| Vascuqol-6 | 56                        | −0.25 (−1.80 to 1.29)             | .75     |
| EQ-SD-SL index | 53                        | 0.02 (−0.05 to 0.08)             | .61     |
| EQ-SD-SL VAS | 55                        | 4.5 (−6.4 to 15.5)               | .41     |

ABI: Ankle-brachial index. CI: confidence interval. MWD: maximal walking distance. PWD: pain-free walking distance. VAS: visual analog scale.
the vascular surgery departments at three hospitals in Norway. Thus, one should be careful about generalizing the results to other patient populations or settings. However, whether the results from the present study are also applicable to patients with more severe stages of PAD should be the subject of further research.

CONCLUSIONS
The results from the present study have shown that treatment with −40 mm Hg INP for 1 hour in the morning and 1 hour in the evening for 12 weeks increased the PWD compared with sham treatment in patients with IC. For patients with a baseline PWD of <200 m, treatment with −40 mm Hg INP increased both PWD and MWD compared with sham treatment.

AUTHOR CONTRIBUTIONS
Conception and design: HH, IM, JH
Analysis and interpretation: HH, EP, LH, JH
Data collection: HH, EP, JH
Writing the article: HH
Critical revision of the article: HH, EP, LH, IM, AS, JH
Final approval of the article: HH, EP, LH, IM, AS, JH
Statistical analysis: HH, LH
Obtained funding: Not applicable
Overall responsibility: HH

REFERENCES
1. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Global Health 2019;7:e1020-30.
2. Norgren L, Hiatt WR, Dormandy JA, Nehrler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33(Suppl 1):S1-75.
3. Regensteiner JG, Hiatt WR, Coll JR, Criqui MH, Treat-Jacobson D, McDermott MM, et al. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med 2008;13:15-24.
4. Gardner AW, Montgomery PS, Scott KJ, Afaq A, Blevins SM. Patterns of ambulatory activity in subjects with and without intermittent claudication. J Vasc Surg 2007;46:1208-14.
5. Lane R, Ellis B, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev 2014;7:CD009900.
6. Fokkenrood HJ, Bendermacher BL, Lauret CJ, Willigendael EM, Prins MH, Teijink JA. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev 2013;8:CD005263.
7. Naylor AR, Vlachopoulos C, Espinola-Klein C, Tepe G, Desormais I, Collet J-P, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), the Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2017;39:763-816.
8. Makris GC, Lattimer CR, Lavida A, Geroulakos G. Availability of supervised exercise programs and the role of structured home-based exercise in peripheral arterial disease. Eur J Vasc Endovasc Surg 2012;44:569-75; discussion: 76.
9. Harwood AE, Smith GE, Cayton T, Broadbent E, Chetter IC. A systematic review of the uptake and adherence rates to supervised exercise programs in patients with intermittent claudication. Ann Vasc Surg 2016;34:280-9.
10. Li Y, Li Z, Chang G, Wang M, Wu R, Wang S, et al. Effect of structured home-based exercise on walking ability in patients with peripheral arterial disease: a meta-analysis. Ann Vasc Surg 2015;29:597-606.
11. Oresanya L, Mazzei M, Bashir R, Farooqui A, Athappan G, Roth S, et al. Systematic review and meta-analysis of high-pressure intermittent limb compression for the treatment of intermittent claudication. J Vasc Surg 2018;67:620-628.
12. Ellul C, Formosa C, Gatt A. Effects of intermittent calf muscle electrical stimulation on walking capacity in claudicants living with type 2 diabetes. J Am Podiatr Med Assoc 2020;110. Article1.
13. Sinkowitz SJ, Gottlieb I. Thrombo-angiitis obliterans: the conservative treatment by Bier’s hyperemia suction apparatus. JAMA 1917;18:961-3.
14. Landsis EM, Hitzrot LH. The clinical value of alternate suction and pressure in the treatment of advanced peripheral vascular disease. Am J Med Sci 1935;189:20-22.
15. Herrmann LG, Reid MR. The conservative treatment of arteriosclerotic peripheral vascular diseases: passive vascular exercises (PAVAEX therapy). Ann Surg 1934;100:750-60.
16. Smyth CN. Effect of suction on blood-flow in ischaemic limbs. Lancet 1969;2:657-9.
17. Himmelstrup H, Himmelstrup B, MehlSEN J, Trap-Jensen J. Effects of vacusac in intermittent claudication- a controlled cross-over study. Clin Physiol 1991;11:263-9.
18. MehlSEN J, Himmelstrup H, Himmelstrup B, Winther K, Trap-Jensen J. Beneficial effects of intermittent suction and pressure treatment in intermittent claudication. Angiology 1995;44:16-20.
19. Hageman D, Fokkenrood HJP, van Deursen BAC, Gommans LNM, Cancrinus E, Scheltinga MRM, et al. Randomized controlled trial of vacuum therapy for intermittent claudication. J Vasc Surg 2020;71:692-701.e1.
20. Afzelius P, Molsted S, Tarnow L. Intermittent vacuum treatment with Vacumed does not improve peripheral artery disease or walking capacity in patients with intermittent claudication. Scand J Clin Lab Invest 2018;78:456-63.
21. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc 1991;23:402-8.
22. Hoel H, Holseth LG, Sandbakk G, Sundhagen JO, Mathiesen I, Hisdal J. The acute effects of different levels of intermittent negative pressure on peripheral circulation in patients with peripheral artery disease. Physiol Rep 2019;7:e14241.
23. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012;126:2890-909.
24. Salisbury DL, Brown RJ, Bronas UG, Kirk LN, Treat-Jacobson D. Measurement of peripheral blood flow in patients with peripheral artery disease: methods and considerations. Vasc Med 2018;23:163-71.
25. EuroQol Research Foundation. EQ-5D-5L User Guide, 2019. Available at: https://euroqol.org/publications/user-guides. Accessed March 2, 2020.

26. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach JJ, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708-15.

27. Larsen ASF, Reiersen AT, Jacobsen MB, Klow NE, Nordanstig J, Morgan M, et al. Validation of the vascular quality of life questionnaire-6 for clinical use in patients with lower limb peripheral arterial disease. Health Qual Life Outcomes 2017;15:184.

28. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ (Clin Res Ed) 2001;323:1123-4.

29. Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with claudication. J Vasc Surg 2012;55:1346-54.

30. Gardner AW, Montgomery PS, Wang M. Minimal clinically important differences in treadmill, 6-minute walk, and patient-based outcomes following supervised and home-based exercise in peripheral artery disease. Vasc Med 2018;23:349-57.

31. Landis EM, Gibbon JH. The effects of alternate suction and pressure on blood flow to the lower extremities. J Clin Invest 1933;12:925-61.

32. Sundby OH, Hoiseth LO, Mathiesen I, Jorgensen JJ, Weedon-Fekjaer H, Hisdal J. Application of intermittent negative pressure on the lower extremity and its effect on macro- and microcirculation in the foot of healthy volunteers. Physiol Rep 2016;4:e12911.

33. Sundby OH, Hoiseth LO, Mathiesen I, Weedon-Fekjaer H, Sundhagen JO, Hisdal J. The acute effects of lower limb intermittent negative pressure on foot macro- and microcirculation in patients with peripheral arterial disease. PloS One 2017;12:e0179001.

34. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med 2002;347:1941-51.

35. Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation 2012;125:130-9.

36. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 1996;23:104-15.

37. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990;81:602-9.

38. Patterson RB, Pinto B, Marcus B, Colucci A, Braun T, Roberts M. Value of a supervised exercise program for the therapy of arterial claudication. J Vasc Surg 1997;25:312-8; discussion: 8-9.

39. Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane Database Syst Rev 2014;10:CD003748.

40. Salihiyah K, Forster R, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev 2015;9:CD005262.

41. van Bemmelen PS, Mattos MA, Faught WE, Mansour MA, Barkmeier LD, Hodgson KJ, et al. Augmentation of blood flow in limbs with occlusive arterial disease by intermittent calf compression. J Vasc Surg 1994;19:1052-8.

42. Labropoulos N, Wierks C, Suflelof B. Intermittent pneumatic compression for the treatment of lower extremity arterial disease: a systematic review. Vasc Med 2002;7:141-8.

43. Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg 2015;61(Suppl):2s-41s.

44. Gerhard-Herman MD, Gornik HL, Barrett C, Barkshe NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 2017;135:e686-725.

45. Fakhry F, Fokkenrood HJ, Spronk S, Teijink JA, Rouwet EV, Hunink MGM. Endovascular revascularisation versus conservative management for intermittent claudication. Cochrane Database Syst Rev 2018;3:CD010512.

46. Sartipy F, Sigvant B, Lundin F, Wahlberg E. Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome. Eur J Vasc Endovasc Surg 2018;55:529-36.

Submitted Jun 25, 2020; accepted Oct 8, 2020.

Additional material for this article may be found online at www.jvascsurg.org.
Supplementary Fig (online only). Relative within-group changes for all outcome variables. Dots indicate mean values; error bars, 95% confidence intervals. ABI, Ankle-brachial index.